Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
11 oct. 2017 08h00 HE
|
Global Blood Therapeutics
First Presentation of Data Specifically Focused on HbSC Genotype Data Presented at Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 ...
Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
03 oct. 2017 08h00 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting its GBT440 program in sickle cell disease...
Global Blood Therapeutics Announces New Employment Inducement Grants
26 sept. 2017 16h05 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 25, 2017, the compensation committee of the...
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
06 sept. 2017 08h00 HE
|
Global Blood Therapeutics
Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month Livestream of...
Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
05 sept. 2017 08h00 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
30 août 2017 16h05 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in...
Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
09 août 2017 16h05 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare...
Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
07 août 2017 16h05 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the second quarter ended...
Global Blood Therapeutics Announces New Employment Inducement Grants
26 juil. 2017 16h05 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 24, 2017, the compensation committee of the Company’s...
Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
10 juil. 2017 08h00 HE
|
Global Blood Therapeutics
SOUTH SAN FRANCISCO, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has expanded the ongoing HOPE-KIDS 1 Study (GBT440-007), a...